Dashboard
Manage Tickers

IMUXIMMUNIC, INC.

Nasdaq immunic-therapeutics.com


$ 1.24 $ -0.03 (-2.36 %)    

Thursday, 09-May-2024 15:59:21 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 1.24
$ 1.32
$ 0.00 x 0
$ 1.25 x 200
$ 1.23 - $ 1.32
$ 0.95 - $ 3.11
204,780
na
120.65M
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-03-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 04-10-2019 03-31-2019 10-Q
22 03-04-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-13-2018 12-31-2017 10-K
27 10-25-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-07-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-02-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 03-08-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-12-2015 03-31-2015 10-Q
38 03-20-2015 12-31-2014 10-K
39 11-13-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immunic-says-it-bolstered-balance-sheet-through-three-tranche-private-placement-totaling-up-to-240m-extending-cash-runway-into-q3-2025-based-on-initial-80m-tranche
Immunic Says It Bolstered Balance Sheet Th...
05/08/2024 10:53:20

immunic-q1-eps-030-misses-026-estimate-cash-and-equivalents-as-of-march-31-2024-were-973m
Immunic Q1 EPS $(0.30) Misses $(0.26) Esti...
05/08/2024 10:33:07

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by ...

immunic-announces-publication-of-extended-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-remitting-multiple-sclerosis-in-neurology-neuroimmunology--neuroinflammation
Immunic Announces Publication of Extended ...
04/30/2024 10:32:02

30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Com...

brookline-capital-initiates-coverage-on-immunic-with-buy-rating-announces-price-target-of-10
Brookline Capital Initiates Coverage On Im...
04/05/2024 08:59:32

Brookline Capital analyst Tyler Bussian initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Ta...

immunic-has-received-a-notice-of-allowance-from-united-states-patent-and-trademark-office-for-patent-covering-composition-of-matter-of-vidofludimus-calcium-imu-838-and-related-production-method-expected-to-provide-protection-into-2039
Immunic Has Received A Notice Of Allowance...
03/20/2024 10:33:36

immunic-and-2-other-stocks-under-2-insiders-are-buying
Immunic And 2 Other Stocks Under $2 Inside...
02/29/2024 15:40:09

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their conf...

immunic-announced-the-presentation-of-data-from-its-phase-2-calliper-and-calvid-1-trials-of-lead-asset-vidofludimus-calcium-imu-838-at-the-americas-committee-for-treatment-and-research-in-multiple-sclerosis-forum-2024
Immunic Announced The Presentation Of Data...
02/29/2024 11:32:15

immunic-q4-eps-048-beats-051-estimate-cash-and-equivalents-as-of-december-31-2023-were-467m
Immunic Q4 EPS $(0.48) Beats $(0.51) Estim...
02/22/2024 11:37:32

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.51) by 5....

earnings-scheduled-for-february-22-2024
Earnings Scheduled For February 22, 2024
02/22/2024 10:27:06

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

immunics-earnings-outlook
Immunic's Earnings Outlook
02/21/2024 19:02:50

whats-going-on-with-immunic-stock
What's Going On With Immunic Stock?
01/05/2024 17:03:42

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranch...

Core News & Articles
Market-Moving News for January 5th
01/05/2024 13:53:53

IMUX: 54% | Immunic, Inc. Announces Private Placement of up to $240M DZSI: 35% | DZS Secures $25M In Funding And Signs Definit...

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
01/05/2024 13:05:58

immunic-inc-announces-private-placement-of-up-to-240m
Immunic, Inc. Announces Private Placement ...
01/05/2024 11:31:55

Immunic, Inc. (NASDAQ:IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipelin...

immunic-receives-notice-of-allowance-for-us-patent-protecting-vidofludimus-calciums-dosing-regimens-in-multiple-sclerosis
Immunic Receives Notice of Allowance for U...
11/21/2023 11:31:59

 Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule the...

earnings-scheduled-for-november-14-2023
Earnings Scheduled For November 14, 2023
11/14/2023 13:23:43

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue o...

immunic-q3-earnings-insights
Immunic: Q3 Earnings Insights
11/14/2023 11:35:22

immunic-q3-eps-051-beats-055-estimate-597m-in-cash-and-cash-equivalents-expected-to-fund-immunic-into-september-of-2024
Immunic Q3 EPS $(0.51) Beats $(0.55) Estim...
11/14/2023 11:33:52

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.55) by 7....

a-preview-of-immunics-earnings
A Preview Of Immunic's Earnings
11/13/2023 16:02:39

reported-earlier-immunic-presents-data-from-phase-1b-clinical-trial-of-imu-856-in-celiac-disease-at-the-united-european-gastroenterology-week-2023
Reported Earlier, Immunic Presents Data Fr...
10/16/2023 06:49:10

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION